Harmony Biosciences Holdings Inc
For the period ended Sep 30, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 29, 2024
HRMY$33.55-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| | | | | | | |
|---|---|---|---|---|---|---|
| · September 30, · December 31, | ||||||
| · 2024 · 2023 | ||||||
| ASSETS · · | ||||||
| CURRENT ASSETS: · · | ||||||
| Cash and cash equivalents | | $387,367 | | $311,660 | ||
| Investments, short-term | | | 23,109 | | | 41,800 |
| Trade receivables, net | | 81,502 | | 74,140 | ||
| Inventory, net | | 6,915 | | 5,363 | ||
| Prepaid expenses | | 16,057 | | 12,570 | ||
| Other current assets | | 7,455 | | 5,537 | ||
| Total current assets | | 522,405 | | 451,070 | ||
| NONCURRENT ASSETS: | | | ||||
| Property and equipment, net | | 750 | | 371 | ||
| Restricted cash | | 270 | | 270 | ||
| Investments, long-term | | | 94,222 | | | 72,169 |
| Intangible assets, net | | 119,225 | | 137,108 | ||
| Deferred tax asset | | | 185,016 | | | 144,162 |
| Other noncurrent assets | | 6,247 | | 6,298 | ||
| Total noncurrent assets | | 405,730 | | 360,378 | ||
| TOTAL ASSETS | | $928,135 | | $811,448 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | ||||
| CURRENT LIABILITIES: | | | ||||
| Trade payables | | $10,532 | | $17,730 | ||
| Accrued compensation | | 14,224 | | 23,747 | ||
| Accrued expenses | | 109,673 | | 99,494 | ||
| Current portion of long-term debt | | | 15,000 | | | 15,000 |
| Other current liabilities | | 11,850 | | 7,810 | ||
| Total current liabilities | | 161,279 | | 163,781 | ||
| NONCURRENT LIABILITIES: | | | ||||
| Long-term debt, net | | 167,847 | | 178,566 | ||
| Other noncurrent liabilities | | 2,205 | | 2,109 | ||
| Total noncurrent liabilities | | 170,052 | | 180,675 | ||
| TOTAL LIABILITIES | | 331,331 | | 344,456 | ||
| COMMITMENTS AND CONTINGENCIES (Note 13) | | | ||||
| STOCKHOLDERS’ EQUITY: | | | ||||
| Common stock—$0.00001 par value; 500,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 57,030,897 and 56,769,081 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | | 1 | | 1 | ||
| Additional paid in capital | | 643,563 | | 610,266 | ||
| Accumulated other comprehensive (loss) income | | | 499 | | | 2 |
| Accumulated deficit | | (47,259) | | (143,277) | ||
| TOTAL STOCKHOLDERS’ EQUITY | | 596,804 | | 466,992 | ||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | | $928,135 | | $811,448 | ||
UNAUDITED CONDENSED CONSOLIDATED
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.